Donlon 1978.

Methods	Allocation: randomly assigned, no further details. Blindness: double (identical drug and placebo capsules). Design: 2 parallel groups, single centre. Duration: 52 weeks. Analysis: intention‐to‐treat not performed in the trial. Country: USA.
Participants	Diagnosis: schizophrenia, no further details. N=25. Age: mean 41 years. Sex: M 12, F 13. History: chronic. Inclusion: no depression, good health, no previous hospitalisation during last 6 months, symptoms stabilised with neuroleptics.
Interventions	1. Trifluoperazine: range 20‐40 mg/day. N=13. 2. Penfluridol: dose range once a week 80‐160 mg plus 6 days of placebo. N=12.
Outcomes	Leaving the study early Global state: (CGI, use of additional medication). Adverse effects: (TESS; ophtalmologic; abnormal laboratory values). Unable to use ‐ Mental state: (BPRS ‐ only graphs, Hamilton's Psychiatric Scale for depression factors ‐ no data). Social state: (Evaluation of Social Functioning factors ‐no data).
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear